Serum enolase-2, high-sensitivity C-reactive protein, and serum cholesterol in smear-positive drug-naïve pulmonary tuberculosis
Autor: | Tariq Zaffar Shaikh, Suhail Ahmed Almani, Ikramuddin Ujjan, Haji Khan Khoharo |
---|---|
Rok vydání: | 2016 |
Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject lcsh:Medicine Gastroenterology serum cholesterol Mycobacterium tuberculosis 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Chronic granulomatous disease Internal medicine medicine 030212 general & internal medicine Enolase-2 media_common biology business.industry C-reactive protein lcsh:R General Medicine biology.organism_classification medicine.disease Drug-naïve Immunology biology.protein Sputum 030211 gastroenterology & hepatology Original Article medicine.symptom business pulmonary tuberculosis medicine.drug Biomedical sciences high-sensitive C-reactive protein |
Zdroj: | Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences Journal of Research in Medical Sciences, Vol 22, Iss 1, Pp 49-49 (2017) |
ISSN: | 1735-1995 |
Popis: | Background Pulmonary tuberculosis (PTB) is a chronic granulomatous disease caused by Mycobacterium tuberculosis. The present study determined the serum human enolase-2 (ENO-2), high-sensitive C-reactive protein (hs-CRP), and serum cholesterol levels as biological marker of disease activity and treatment response in smear-positive drug-naive PTB. Materials and methods This case-control study was done in the Department of Medicine, Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro/Hyderabad, Sindh, from January 2015 to April 2016. Thirty-five sputum smear-positive drug-naive PTB patients and thirty controls were studied. MTB culture and drug sensitivity were performed at the Diagnostic and Research Laboratory of LUMHS. Serum ENO-2, hs-CRP, and serum cholesterol were estimated at baseline, 3rd and 6th month of antituberculosis (TB) therapy. Results Serum ENO-2 and hs-CRP were found raised in PTB compared to controls and showed decrease of 13% and 21.55%, 19.6% and 31.5% at 3rd and 6th month, respectively (P = 0.0001). Serum ENO-2 revealed positive correlation with hs-CRP (r = 0.734, P = 0.0001), and serum cholesterol revealed negative correlation with ENO-2 and hs-CRP (r = -0.509, P = 0.0001) and (r = -0.566, P = 0.0001), respectively. Conclusion The present study reports the baseline ENO-2 and hs-CRP were raised, and serum cholesterol was low in smear-positive PTB patients and the ENO-2 and hs-CRP were reduced by anti-TB drug therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |